The U.S. Preventive Services Task Force (USPSTF) has released draft recommendations calling for all adult medical patients younger than age 65 years to undergo screening for anxiety.

The latest findings from the Pharmacy Workplace and Well-being Reporting (PWWR) initiative, which was launched by APhA and the National Alliance of State Pharmacy Associations (NASPA) last fall, are now available.

A study by researchers at Harvard has identified the presence of SARS-CoV-2’s spike protein in the blood of long COVID patients up to 1 year after infection, but not in people who fully recovered from the disease.

In response to the Dobbs v. Jackson ruling, APhA has created numerous resources to help pharmacists navigate the nuances of how pharmacy practice has been affected.

In a new study, researchers sought to examine differences in the prescribing of SGLT-2 inhibitors and glucagon-like peptide-1 (GLP-1) agonists among adults with type 2 diabetes along ethnic and racial groups. The American Diabetes Association recommends these as first-line treatments with or without metformin for people with type 2 diabetes who have or who are at high risk for atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease.